IO Biotech IOBTQ
IOBTQ
$0.00 +0.00 (+0.00%)
At close: Oct 1, 2026 · 4:00 PM EDT

IO Biotech, Inc. (IOBTQ) Change in Account Payables (2020 - 2025)

Updated

IO Biotech (IOBTQ) recorded Change in Account Payables of $50,000 in Q3 2025, down 79.1% from $239,000 a year earlier and down 85.3% from the prior quarter.

Analysis

IO Biotech, Inc. (IOBTQ) Change in Account Payables (2020 - 2025) Analysis & Trends

On a TTM basis, IO Biotech's Change in Account Payables came in at $331,000 as of Sep 30, 2025; for FY2024, it was $782,000.

  • Across earlier years, Change in Account Payables came in at -$126,000 in FY2023, $77,000 in FY2022 (-97.7%), $3.41 million in FY2021 and -$475,000 in FY2020.
  • Quarterly Change in Account Payables has ranged from -$2.77 million in Q4 2023 to $2.45 million in Q2 2022 over the past five years.
  • On a year-over-year basis, Change in Account Payables rose in 1 of the last four quarters, with growth averaging 59.4%.
  • Per Business Quant, the preceding three quarters came in at $339,000 (Q2 2025), $538,000 (Q1 2025) and -$596,000 (Q4 2024).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 50,000.00
Jun 30, 2025 339,000.00
Mar 31, 2025 538,000.00
Dec 31, 2024 -596,000.00
Sep 30, 2024 239,000.00
Jun 30, 2024 1.18 Mn
Mar 31, 2024 -38,000.00
Dec 31, 2023 -2.77 Mn
Sep 30, 2023 2.18 Mn
Jun 30, 2023 204,000.00
Mar 31, 2023 256,000.00
Dec 31, 2022 1.84 Mn
Sep 30, 2022 -2.37 Mn
Jun 30, 2022 2.45 Mn
Mar 31, 2022 -1.84 Mn
Dec 31, 2021 1.76 Mn
Sep 30, 2021 470,000.00
Jun 30, 2021 496,000.00
Mar 31, 2021 678,000.00
Dec 31, 2020 -434,000.00
API Access

IO Biotech, Inc. Change in Account Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-account-payables&ticker=IOBTQ&period=max&api_key=YOUR_API_KEY